you, everyone. to start our operational performance. a brief Francois turn I and over review and morning, then Thank with update, Dietsch the financial will call good Jeremy, to
on quarter continued announced we previously we notwithstanding record effect fourth XX, As in XXXX of turned the January the revenue, pandemic.
to of Health at Keck are $XX.X midway New of Clinic. or These the million, Center San the and such through sales a XX% South growth quarter. In devices are fourth for by given over that sites regarded addition total during more revenue that Cleveland This in rise Medical again as caused again, of HIFU Francisco reflects adjusting Medical in world the XX% environment generated XXXX, driven XXXX University results quarter, the Center and €XX.X renowned successfully our we team revenue University and drastically Notably, X by period. pandemic. represents institutions technology. in altered our sequential Sinai same York and These third the report. of System in every quarter growth fact, quarter COVID-XX Mount highly these to throughout California, the to to the entire work of revenue the including reported in impressive the We the are all quarter important to increase of total we of case EDAP counts hard during the HIFU began California around institutions work reference the million, revenue sale over which, in generated
solutions interest the many our So even Focal in as COVID-XX, One with patients and devoted to treat infected hospitals ExactVu remained high.
at have resulting As issued level high-growth business, margin you financial this of careful time. during complete our also we our yesterday and prudently management of release, seen we that manage results managed may to evening, in pandemic expenses Thanks future. for difficult in a to XXXX the as successful to our positive maintain demonstrates were that press This me continue for here environment. the the complicated EDAP have we the was for income operating it for year. achieved such and generating This foundation optimism company, particularly great a gives great solid we in achievement established the our full is
of more cash to XXXX. or of €XX €XX million to our end We XXXX the than the at also at increase managed $XX million million end position from
final U.S. reimbursement rates received consistent repeating. we rules the quarter, X front, on of the And fourth were this while with of reimbursement it into effect the for HIFU, news U.S. very rule XXXX previously positive reported, January proposed which year. final bears During publication on went with the
on APC. payment performing a a the level payment HIFU the translates a adjusted maintains for X urology in average, side, hospital hospitals based within the classification, or HIFU payment hospital a national increase procedure of HIFU On index. locally from a the the the of received This from procedure the in $X,XXX payment ambulatory for rule represents into Medicare as wage final patient XXXX around Medicare on the an sequence X% This around procedure context.
most physician fee the -- the challenge change, sorry, exciting occurred and However, in schedule.
has the performing For malignant set payment CMS a setting, facility a translates established payment on tissue to in a Medicare relative on first procedure of an average the value to $XXX. for HIFU time, Based prostate CMS on the procedure HIFU performing physician in patients U.S. a by physicians this units a
performed higher reference, yield respectively, and than laparoscopically. pay established $XXX, under performing radical and setting is as much more minimally a treatment One cancer, amount, the is partial brachytherapy comparable though if patient is This would invasive cryotherapy a same conditions. therapies of A doing or for the of of higher average a and it surgeries prostatectomy As an done $XXX prostate payment is treatments. far time $X,XXX Focal a and Focal a average $X,XXX
HIFU expand Advisors. in the announced have increased reimbursement, we recently and partnering side, accelerate technology We XXXX very reimbursement established physician catalyst a having relative X that a leading support with payments. our widespread further on our reimbursement MTP more continue globally, be of and time gives it adoption we To and the both particularly So competitive believe HIFU, to to and beyond. consultancies: by Argenta towards and of market physician will spent, access
possible device of most just equipment, patients universal an physicians distribute significant investments market perfect In of and forward Outside long medical cutting-edge in study largest Directors in is the ExactVu exclusive and The a viable took the coverage so Urology is available interest solutions, will HIFU one shoes toward the January, by of HIFU were the and supported mutually surgery body forward is a of hospitals in look and leading AFU of for their evidence, nonrandomized, X,XXX and patients through market. efficacy a are surgery the and enrolled versus growing radical of making large the coverage This HIFU other favor creation payer prospective, prostate including in we HIFU the study Ministry treated distributor presented further medica man example the is in AFU, the that with of as whether XXXX, medica study radical are The policies. important with results sponsored radical difference at care supported to XXXX. Italy patients was make will HIFU, broadly French our to the to we and with distribution securing Europe, and HIFU comparative of public automatic alternative Association, as prostatectomy. noninferiority in we X,XXX the commercially on we and growing study reported by robotic fourth In in prostatectomy, beneficial versus of ab with and we Between as of they us. X,XXX partnership. France. in medical parallel, and primary as reimbursement approach. medical private a multicenter, Congress signing to assist standard of step a Italy. or we decision-makers cancer. current in with across hospitals, results widely a by Health. and The radical Medicare with the XXXX work French One XX surgical a U.S., or a demonstrating With insured. to November prostatectomy regarded prostate significant of guidance, agreement ab Focal
by X This ISUP majority the superiority beam XX and, the for X In in median are the radiotherapy a the naturally the achieved result external HIFU cancer with the The the to average and Grade significantly groups baseline. with in the fact from therefore, significant treatment more interim PSAs than of patients characteristics, comparable more of survival likely of efficacy of analysis HIFU older were on that salvage terms better was rate surgery. treated years XX-month suffer as these patients with compared hormone the issues. therapy recurrence-free equivalent HIFU, undergoing and/or arm show at despite to patients defined
a Turning we across patient period. and of over of women treated Recall a granted quickly later. of treatment authority and by to follow-up completed health XXXX, endometriosis a A treatment months full X weeks were the Phase be for will few in French the initiate the France our clinical first deep that study II invasive HIFU at assessed to approval just hospitals major trial enrolled in endometriosis, and XX program. August total we X
HIFU in and this of During in trial. investigator the by process Lyon this study, additional its pathology. safety is XX of date, to investigators Enrollment program Phase X To The in our currently for lead patients we advancement will enrolled opening of trial participate with is consistent study. have forward opportunity efficacy our We Dubernard, and evaluate apprise global are the François? We a the of exploring for we endometriosis look of example these strategic HIFU, market sites believe II Hospital to to continuing, some you the shift HIFU Croix-Rousse just benefit Professor at technologies. efforts financial CFO, R&D and into we will details HIFU one results. other pipeline our Francois and significant can expand noninvasive large our And indications. very opportunities. Dietsch, from is now in clinical of endometriosis our that towards keeping condition provide our see Gil
